ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial accessibility, and responsible innovation. Our approach to licensing, evidenced by over 145 licenses already granted worldwide, proves that sophisticated IP management can accelerate rather than hinder scientific progress and support groundbreaking innovation. This approach has broken down traditional barriers to entry, enabling organisations of all sizes to responsibly access and participate in the CRISPR biotech revolution. Based on Emmanuelle Charpentier’s & Jennifer Doudna’s Nobel Prize winning discovery of how CRISPR/Cas9works, and the transformational impact it had as the gold standard